These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 28917533

  • 1. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
    Cervello M, Pitarresi G, Volpe AB, Porsio B, Balasus D, Emma MR, Azzolina A, Puleio R, Loria GR, Puleo S, Giammona G.
    J Control Release; 2017 Nov 28; 266():47-56. PubMed ID: 28917533
    [Abstract] [Full Text] [Related]

  • 2. Biotinylated polyaminoacid-based nanoparticles for the targeted delivery of lenvatinib towards hepatocarcinoma.
    Varvarà P, Emanuele Drago S, Esposito E, Campolo M, Mauro N, Calabrese G, Conoci S, Morganti D, Fazio B, Giammona G, Pitarresi G.
    Int J Pharm; 2024 Sep 05; 662():124537. PubMed ID: 39079592
    [Abstract] [Full Text] [Related]

  • 3. Galactosylated polymeric carriers for liver targeting of sorafenib.
    Craparo EF, Sardo C, Serio R, Zizzo MG, Bondì ML, Giammona G, Cavallaro G.
    Int J Pharm; 2014 May 15; 466(1-2):172-80. PubMed ID: 24607205
    [Abstract] [Full Text] [Related]

  • 4. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
    Tang X, Chen L, Li A, Cai S, Zhang Y, Liu X, Jiang Z, Liu X, Liang Y, Ma D.
    Drug Deliv; 2018 Nov 15; 25(1):1484-1494. PubMed ID: 29916268
    [Abstract] [Full Text] [Related]

  • 5. PHEA-graft-polybutylmethacrylate copolymer microparticles for delivery of hydrophobic drugs.
    Licciardi M, Di Stefano M, Craparo EF, Amato G, Fontana G, Cavallaro G, Giammona G.
    Int J Pharm; 2012 Aug 20; 433(1-2):16-24. PubMed ID: 22575755
    [Abstract] [Full Text] [Related]

  • 6. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
    Cao H, Wang Y, He X, Zhang Z, Yin Q, Chen Y, Yu H, Huang Y, Chen L, Xu M, Gu W, Li Y.
    Mol Pharm; 2015 Mar 02; 12(3):922-31. PubMed ID: 25622075
    [Abstract] [Full Text] [Related]

  • 7. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
    Zhang J, Wang T, Mu S, Olerile LD, Yu X, Zhang N.
    Nanomedicine (Lond); 2017 Apr 02; 12(8):911-925. PubMed ID: 28339312
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Enhanced oral absorption of sorafenib via the layer-by-layer deposition of a pH-sensitive polymer and glycol chitosan on the liposome.
    Zhao M, Lee SH, Song JG, Kim HY, Han HK.
    Int J Pharm; 2018 Jun 10; 544(1):14-20. PubMed ID: 29655795
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Acidic pH-Triggered Drug-Eluting Nanocomposites for Magnetic Resonance Imaging-Monitored Intra-arterial Drug Delivery to Hepatocellular Carcinoma.
    Park W, Chen J, Cho S, Park SJ, Larson AC, Na K, Kim DH.
    ACS Appl Mater Interfaces; 2016 May 25; 8(20):12711-9. PubMed ID: 27159350
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
    Zhang L, Gong F, Zhang F, Ma J, Zhang P, Shen J.
    Int J Nanomedicine; 2013 May 25; 8():1517-24. PubMed ID: 23620667
    [Abstract] [Full Text] [Related]

  • 15. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
    Zhao P, Li M, Wang Y, Chen Y, He C, Zhang X, Yang T, Lu Y, You J, Lee RJ, Xiang G.
    Acta Biomater; 2018 May 25; 72():248-255. PubMed ID: 29555460
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
    Zhang J, Hu J, Chan HF, Skibba M, Liang G, Chen M.
    Nanomedicine; 2016 Jul 25; 12(5):1303-11. PubMed ID: 26964482
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells.
    Bondì ML, Botto C, Amore E, Emma MR, Augello G, Craparo EF, Cervello M.
    Int J Pharm; 2015 Sep 30; 493(1-2):75-85. PubMed ID: 26211902
    [Abstract] [Full Text] [Related]

  • 20. Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma.
    Tom G, Philip S, Isaac R, Praseetha PK, Jiji SG, Asha VV.
    Life Sci; 2018 Aug 01; 206():10-21. PubMed ID: 29709652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.